Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma

Cyclophosphamide exhibits the weakest therapeutic effect compared with vincristine and doxorubicin in the CHOP (C, cyclophosphamide; H, doxorubicin; O, vincristine; and P, prednisolone) chemotherapeutic protocol for the treatment of canine lymphoma. Twenty dogs with multicentric lymphoma were treated using the LHOP protocol, which used l-asparaginase in place of cyclophosphamide, and the outcomes were historically compared with those of dogs that received CHOP chemotherapy in the same institution. No significant differences were found in age (p = 0.107), body weight (p = 0.051), sex (p = 0.453), clinical stage V (p = 1), substage b (p = 0.573), T-cell phenotype (p = 0.340), overall response (p = 1), and hypercalcaemia status (p = 1) between the LHOP and CHOP groups. The adverse effects of l-asparaginase were well tolerated and self-limiting. The median PFS (progression-free survival) and median ST (survival time) in the LHOP group were 344 days (range: 28–940 days) and 344 days (range: 70–940 days), respectively. The median PFS and median ST in the CHOP group were 234 days (range: 49–1822 days) and 314 days (range: 50–1822 days), respectively. The dogs that received LHOP chemotherapy had a significantly longer PFS than the dogs that received CHOP chemotherapy (p = 0.001). No significant difference was observed in ST between the LHOP and CHOP groups (p = 0.131). Our study findings thus indicate that the LHOP protocol can be used as a first-line chemotherapeutic protocol in canine multicentric lymphoma.

Download Full-text

Incidence and treatment of feline renal lymphoma: 27 cases

Journal of Feline Medicine and Surgery ◽

10.1177/1098612x20984363 ◽

2021 ◽

pp. 1098612X2098436

Author(s):

Ashlyn G Williams ◽

Ann E Hohenhaus ◽

Kenneth E Lamb

Keyword(s):

Median Survival ◽

Clinical Stage ◽

Large Population ◽

Clinical Signs ◽

Treatment Protocol ◽

Central Nervous System Involvement ◽

Data Set ◽

Hematopoietic Malignancy ◽

Renal Lymphoma ◽

Multicentric Lymphoma

Objectives Lymphoma is the most common feline hematopoietic malignancy. Incidence of renal lymphoma has not been reported as a subset of a large population of feline lymphoma cases. Previous studies have reported renal lymphoma as both a singular entity as well as a component of multicentric disease. The clinical presentation, diagnostic evaluation, therapy and outcomes related to renal lymphoma have not been reported since Mooney et al in 1987. This retrospective study aimed to describe the incidence of renal lymphoma, clinical signs, treatment and survival. Methods Using a database of cats diagnosed with lymphoma between January 2008 and October 2017, cats with renal lymphoma were selected for further analysis. Cases were retrospectively staged according to Mooney et al (1987) and Gabor et al (1998). Data collected included age, clinical signs, clinicopathologic data, diagnostic imaging findings, lymphoma diagnostic method(s), treatment protocol(s) and survival time. Analyses comparing median survival based on therapy administered, renal lymphoma vs multicentric lymphoma, central nervous system involvement, presence of azotemia, anemia and International Renal Interest Society (IRIS) stage at diagnosis were performed. Results From a population of 740 cats with lymphoma, 27 cats had renal lymphoma (incidence, 3.6%), and 14 of those cats had multicentric lymphoma. Fewer stage IV and V cases were identified in this data set compared with Mooney et al; however, not all cats were completely staged. Median survival (range) for cats receiving corticosteroids alone compared with those receiving an L-CHOP (L-asparaginase, vincristine, cyclophosphamide, doxorubicin, prednisolone)-based protocol was 50 days (20–1027 days) in the corticosteroid group and 203 days (44–2364 days) for the L-CHOP group ( P = 0.753) for cats that died secondary to lymphoma. Conclusions and relevance Neither clinical stage nor other factors were predictive of survival. Prospective studies are required to determine the optimal chemotherapy protocol.

Download Full-text

Nebulized dexmedetomidine as a rescue agent for an emergent awake tracheostomy: A case report

Journal of Clinical Anesthesia ◽

10.1016/j.jclinane.2021.110465 ◽

2021 ◽

Vol 75 ◽

pp. 110465

Author(s):

Mohammed Rabi Andaloussi

Keyword(s):

Case Report ◽

Rescue Agent

Download Full-text

Lipoic acid as a rescue agent for adriamycin-induced hyperlipidemic nephropathy in rats

Nutrition Research ◽

10.1016/s0271-5317(03)00004-6 ◽

2003 ◽

Vol 23 (4) ◽

pp. 539-548 ◽

Cited By ~ 3

Author(s):

K.P. Malarkodi ◽

P. Varalakshmi

Keyword(s):

Lipoic Acid ◽

Rescue Agent

Download Full-text

Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?

The Veterinary Journal ◽

10.1016/j.tvjl.2016.04.013 ◽

2016 ◽

Vol 213 ◽

pp. 87-89 ◽

Cited By ~ 2

Author(s):

Shang-Lin Wang ◽

Jih-Jong Lee ◽

Albert Taiching Liao

Keyword(s):

Temporal Association ◽

Weakest Link ◽

Multicentric Lymphoma

Download Full-text

Characterizing Circulating Nucleosomes in the Plasma of Dogs with Lymphoma

10.21203/rs.3.rs-318227/v1 ◽

2021 ◽

Author(s):

Christopher Dolan ◽

Tasha Miller ◽

Jarvis Jill ◽

Jason Terrell ◽

Theresa Kelly ◽

...

Keyword(s):

Fold Increase ◽

Monitoring Tool ◽

Treatment Results ◽

Canine Lymphoma ◽

Histone Octamer ◽

Objective Monitoring ◽

Remission Status ◽

T Cell Lymphomas ◽

Healthy Dogs ◽

Multicentric Lymphoma

Abstract Background: Nucleosomes consist of DNA wrapped around a histone octamer core like beads on a string so that DNA can be condensed as chromatin into chromosomes. Diseases such as cancer or inflammation lead to cell death where chromatin is fragmentated and released as mononucleosomes into the blood. The Nu.QTM H3.1 assay measures total nucleosome concentration in plasma of humans and has been used to detect and identify cancer even at early stages. The objectives of this study were to determine if nucleosome levels could be used to distinguish between healthy dogs and dogs with various stages of lymphoma (LSA) using the Nu.Q™ H3.1 assay. A total of 126 dogs diagnosed with LSA and 134 healthy controls were recruited for this study. Plasma was collected from each dog and stored in K2-EDTA tubes. The LSA patient samples were recruited from TAMU or purchased from various biobanks. All control cases were recruited from TAMU. Samples were also collected longitudinally from 3 dogs undergoing treatment for multicentric lymphoma at TAMU as a pilot study to investigate the pattern of nucleosome concentrations in plasma during treatment. Results: Dogs with LSA had an approximately 7-fold increase in their plasma nucleosome concentrations compared to controls (AUC 87.8%). Nucleosome concentrations increased with cancer stage and dogs with B cell lymphomas had significantly higher nucleosome concentrations than dogs with T cell lymphomas. Nucleosome concentrations from serially monitored patients were elevated at diagnosis and progression with subsequent decreases in nucleosome concentration that corresponded to clinically detectable responses to therapy. Conclusions: The Nu.QTM H3.1 assay was able to reliably detect elevated nucleosome concentrations in the plasma of dogs with LSA. Furthermore, it appears that nucleosomes are useful for differentiating cancer from healthy individuals in canines. Results from serially monitored patients indicate that nucleosomes could be an objective monitoring tool for remission status in canine lymphoma patients.

Download Full-text